Statins and type 2 diabetes mellitus: An update after 1 year

Current Pharmaceutical Design

Volumn 22, Issue 18, 2016, Pages 2723-2725

  Katsiki, Niki ^a   Athyros, Vasilios G ^a   Karagiannis, Asterios ^a   Mikhailidis, Dimitri P ^b  

^a ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Cancer; Diabetes mellitus; Ezetimibe; IMPROVE IT; New onset diabetes; Statins

Indexed keywords

EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; HEALTH CARE COST; HUMAN; INSULIN SENSITIVITY; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE;

DIABETES MELLITUS, TYPE 2; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;

EID: 84974690891     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612822666160125114626     Document Type: Article

References (53)

1. Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. The role of statins in the treatment of type 2 diabetes mellitus: an update. Curr Pharm Des 2014; 20: 3665-74.
2. Katsiki N, Rizzo M, Mikhailidis DP, Mantzoros CS. New-onset diabetes and statins: throw the bath water out, but, please, keep the baby! Metabolism 2015; 64: 471-5.
3. Cannon CP, Blazing MA, Giugliano RP, et al. IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372: 2387-97.
4. Husain NE, Hassan AT, Elmadhoun WM, Ahmed MH. Evaluating the safety of Liptruzet (ezetimibe and atorvastatin): what are the potential benefits beyond low-density lipoprotein cholesterol-lowering effect? Expert Opin Drug Saf 2015: 1-11.
5. Ohbu-Murayama K, Adachi H, Hirai Y, et al. Ezetimibe combined withstandard diet and exercise therapy improves insulin resistance andatherosclerotic markers in patients with metabolic syndrome. J Diabetes Investig 2015; 6: 325-33.
6. Tsunoda T, Nozue T, Yamada M, Mizuguchi I, Sasaki M, Michishita I. Effects of ezetimibe on atherogenic lipoproteins and glucose metabolism in patients withdiabetes and glucose intolerance. Diabetes Res Clin Pract 2013; 100: 46-52.
7. Katsiki N, Theocharidou E, Karagiannis A, Athyros VG, Mikhailidis DP. Ezetimibe therapy for dyslipidemia: an update. Curr Pharm Des 2013; 19: 3107-14.
8. Averna M. The effect of ezetimibe on NAFLD. Atheroscler Suppl 2015; 17: 27-34.
9. Athyros VG, Tziomalos K, Katsiki N, Doumas M, Karagiannis A, Mikhailidis DP. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update. World J Gastroenterol 2015; 21: 6820-34.
10. Banach M, Rizzo M, Toth PP, et al. Statin intolerance-an attempt at a unified definition. Position paper from an international lipid expert panel. Arch Med Sci 2015; 11: 1-23.
11. Stroes ES, Thompson PD, Corsini A, et al. European Atherosclerosis Society Consensus Panel. Statin-associated muscle symptoms: impact on statin therapy-European atherosclerosis society consensus panel statement on assessment, Aetiology and Management. Eur Heart J 2015; 36: 1012-22.
12. Harshman LC, Wang X, Nakabayashi M, et al. Statin Use at the time of initiation of androgen deprivation therapy and time to progression in patients with hormone-sensitive prostate cancer. JAMA Oncol 2015; 1: 495-504.
13. Zanders MM, van Herk-Sukel MP, Vissers PA, Herings RM, Haak HR, van de Poll-Franse LV. Are metformin, statin and aspirin use still associated with overall mortality among colorectal cancer patients with diabetes if adjusted for one another? Br J Cancer 2015; 113(3): 403-10.
14. Ling Y, Yang L, Huang H, et al. Prognostic significance of statin use in colorectal cancer: A systematic review and meta-analysis. Medicine (Baltimore) 2015; 94: e908.
15. Cai H, Zhang G, Wang Z, Luo Z, Zhou X. Relationship between the use of statins and patient survival in colorectal cancer: a systematic review and meta-analysis. PLoS One 2015; 10: e0126944.
16. Zhong S, Zhang X, Chen L, Ma T, Tang J, Zhao J. Statin use and mortality in cancer patients: Systematic review and meta-analysis of observational studies. Cancer Treat Rev 2015; 41: 554-67.
17. Pradelli D, Soranna D, Zambon A, et al. Statins use and the risk of all and subtype hematological malignancies: a meta-analysis of observational studies. Cancer Med 2015; 4: 770-80.
18. Hoffmeister M, Jansen L, Rudolph A, et al. Statin use and survival after colorectal cancer: the importance of comprehensive confounder adjustment. J Natl Cancer Inst 2015; 107: djv045.
19. Shao YY, Hsu CH, Yeh KH, et al. Statin use is associated with improved prognosis of colorectal cancer in taiwan. Clin Colorectal Cancer 2015. pii: S1533-0028(15)00032-8.
20. Desai P, Lehman A, Chlebowski RT, et al. Statins and breast cancer stage and mortality in the Women's health initiative. Cancer Causes Control 2015; 26: 529-39.
21. Murtola TJ, Visvanathan K, Artama M, Vainio H, Pukkala E. Statin use and breast cancer survival: a nationwide cohort study from Finland. PLoS One 2014; 9: e110231.
22. Sehdev A, Shih YC, Huo D, Vekhter B, Lyttle C, Polite B. The role of statins for primary prevention in non-elderly colorectal cancer patients. Anticancer Res 2014; 34: 5043-50.
23. Cardwell CR, Hicks BM, Hughes C, Murray LJ. Statin use after colorectal cancer diagnosis and survival: a population-based cohort study. J Clin Oncol 2014; 32: 3177-83.
24. Chan JM, Kenfield SA, Paciorek A, Platz EA, Giovannucci EL, Stampfer M. Post-diagnostic statin use and the risk of lethal prostate cancer in the Health Professionals Follow-up Study. Cancer Epidemiol Biomarkers Prev 2015; 24(10): 1638-40.
25. Kantor ED, Lipworth L, Fowke JH, Giovannucci EL, Mucci LA, Signorello LB. Statin use and risk of prostate cancer: Results from the southern community cohort study. Prostate 2015; 75(13): 1384-93.
26. Pastore A, Palleschi G, Fuschi A, et al. Can daily intake of aspirin and/or statins influence the behavior of non-muscle invasive bladder cancer? A retrospective study on a cohort of patients undergoing transurethral bladder resection. BMC Cancer 2015; 15: 120.
27. Nordström T, Clements M, Karlsson R, Adolfsson J, Grönberg H. The risk of prostate cancer for men on aspirin, statin or antidiabetic medications. Eur J Cancer 2015; 51: 725-33.
28. Viers BR, Houston Thompson R, et al. The association of statin therapy with clinicopathologic outcomes and survival among patients with localized renal cell carcinoma undergoing nephrectomy. Urol Oncol 2015; 33(9): 388.e11-8.
29. Yoon LS, Goodman MT, Rimel BJ, Jeon CY. Statin use and survival in elderly patients with endometrial cancer. Gynecol Oncol 2015; 137: 252-7.
30. Cuaron J, Pei X, Cohen GN, et al. Statin use not associated with improved outcomes in patients treated with brachytherapy for prostate cancer. Brachytherapy 2015; 14: 179-84.
31. Huang H, Cui XX, Chen S, et al. Combination of Lipitor and Celebrex inhibits prostate cancer VCaP cells in vitro and in vivo. Anticancer Res 2014; 34: 3357-63.
32. Chen-Pin W, Javier H, Lorenzo C, et al. Statins and finasteride use differentially modify the impact of metformin on prostate cancer incidence in men with type 2 diabetes. Ann Transl Med Epidemiol 2014; 1. pii: 1004.
33. Danzig MR, Kotamarti S, Ghandour RA, et al. Synergism between metformin and statins in modifying the risk of biochemical recurrence following radical prostatectomy in men with diabetes. Prostate Cancer Prostatic Dis 2015; 18: 63-8.
34. Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Highdensity lipoprotein, vascular risk, cancer and infection: a case of quantity and quality? Curr Med Chem 2014; 21: 2917-26.
35. Coppola JA, Shrubsole MJ, Cai Q, et al. Plasma lipid levels and colorectal adenoma risk. Cancer Causes Control 2015; 26: 635-43.
36. Athyros VG, Katsiki N, Doumas M, Karagiannis A, Mikhailidis DP. Effect oftobaccosmoking and smoking cessation on plasma lipoproteins and associated majorcardiovascular risk factors: a narrative review. Curr Med Res Opin 2013; 29: 1263-74.
37. Milionis HJ, Rizos E, Mikhailidis DP. Smoking diminishes the beneficialeffect of statins: observations from the landmark trials. Angiology 2001; 52: 575-87.
38. Lötsch F, Königsbrügge O, Posch F, Zielinski C, Pabinger I, Ay C. Statins are associated with low risk of venous thromboembolism in patients with cancer: a prospective and observational cohort study. Thromb Res 2014; 134: 1008-13.
39. Lassila R, Jula A, Pitkäniemi J, Haukka J. The association of statin use with reduced incidence of venous thromboembolism: a population-based cohort study. BMJ Open 2014; 4: e005862.
40. Chotenimitkhun R, D'Agostino R Jr, Lawrence JA, et al. Chronic statin administration may attenuate early anthracycline-associated declines in left ventricular ejection function. Can J Cardiol 2015; 31: 302-7.
41. Pavan LM, Rêgo DF, Elias ST, De Luca Canto G, Guerra EN. In vitro anti-tumor effects of statins on head and neck squamous cell carcinoma: A systematic review. PLoS One 2015; 10: e0130476.
42. Cederberg H, Stančáková A, Yaluri N, Modi S, Kuusisto J, Laakso M. Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort. Diabetologia 2015; 58: 1109-17.
43. Kolovou GD, Mikhailidis DP, Kovar J, et al. Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement. Curr Vasc Pharmacol 2011; 9: 258-70.
44. Bozzetto L, Annuzzi G, Corte GD, et al. Ezetimibe beneficially influences fasting and postprandial triglyceride-rich lipoproteins in type 2 diabetes. Atherosclerosis 2011; 217: 142-8.
45. Lee SH, Park S, Kang SM, Jang Y, Chung N, Choi D. Effect of atorvastatinmonotherapy and low-dose atorvastatin/ezetimibe combination on fasting and postprandial triglycerides in combined hyperlipidemia. J Cardiovasc Pharmacol Ther 2012; 17: 65-71.
46. Sugiyama T, Tsugawa Y, Tseng CH, Kobayashi Y, Shapiro MF. Different time trends of caloric and fat intake between statin users and nonusers among US adults: Gluttony in the time of statins? JAMA Intern Med 2014; 174: 1038-45.
47. Athyros VG, Mikhailidis DP. Therapy: Caloric and fat intake in statin users. Nat Rev Endocrinol 2014; 10: 450-1.
48. Giugliano RP, Sabatine MS. Are PCSK9 inhibitors the next breakthrough in the cardiovascular field? J Am Coll Cardiol 2015; 65: 2638-51.
49. Robinson JG, Farnier M, Krempf M, et al. ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1489-99.
50. Bonnefond A, Yengo L, Le May C, et al. DESIR study group. The loss-of-function PCSK9 p.R46L genetic variant does not alter glucose homeostasis. Diabetologia 2015; 58: 2051-5.
51. Yang SH, Li S, Zhang Y, et al. Positive correlation of plasma PCSK9 levels with HbA1c in patients with type 2 diabetes. Diabetes Metab Res Rev 2015 Sep 17. doi: 10.1002/dmrr.2712. [Epub ahead of print].
52. Nguyen V, deGoma EM, Hossain E, Jacoby DS. Updated cholesterol guidelines and intensity of statin therapy. J Clin Lipidol 2015; 9: 357-9.
53. Serban MC, Banach M, Mikhailidis DP. Clinical implications of the IMPROVE-ITtrial in the light of current and future lipid-lowering treatment options. Expert Opin Pharmacother 2015 Nov 11. [Epub ahead of print] PubMed PMID: 26559810.